Kevin Waters - 16 Sep 2024 Form 4 Insider Report for PROCEPT BioRobotics Corp (PRCT)

Role
EVP, CFO
Signature
/s/ Jonathan Stone, Attorney-in-Fact for Kevin Waters
Issuer symbol
PRCT
Transactions as of
16 Sep 2024
Net transactions value
-$2,062,679
Form type
4
Filing time
18 Sep 2024, 17:59:00 UTC
Previous filing
20 Mar 2024
Next filing
17 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRCT Common Stock Options Exercise $71,945 +15,917 +17% $4.52 112,013 16 Sep 2024 Direct
transaction PRCT Common Stock Options Exercise $41,418 +9,083 +8.1% $4.56 121,096 16 Sep 2024 Direct
transaction PRCT Common Stock Sale $542,821 -6,623 -5.5% $81.96 114,473 16 Sep 2024 Direct F1, F2
transaction PRCT Common Stock Sale $1,486,518 -17,977 -16% $82.69 96,496 16 Sep 2024 Direct F1, F3
transaction PRCT Common Stock Sale $33,340 -400 -0.41% $83.35 96,096 16 Sep 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRCT Stock Option (Right to Buy) Options Exercise $71,945 -15,917 -100% $4.52 0 16 Sep 2024 Common Stock 15,917 $4.52 Direct F5
transaction PRCT Stock Option (Right to Buy) Options Exercise $41,418 -9,083 -17% $4.56 44,160 16 Sep 2024 Common Stock 9,083 $4.56 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.30 to $82.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.30 to $83.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.34 to $83.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F5 The Stock Option was granted on October 23, 2018 and vested over a four year period.
F6 The Stock option was granted on December 12, 2019 and vested over a four year period.